Open AccessPattern of resistance to second line anti-tuberculosis drugs and associated risk factors among multidrug-resistant patients of pulmonary tuberculosis from Agra region of Uttar Pradesh, North India
Author(s) -
Anjali Yadav,
Suman Singh,
Rakesh Sharma,
Santosh Kumar,
Ajay Vir Singh,
Deepika Chauhan
Publication year - 2022
Language(s) - English
Resource type - Journals
ISSN - 2582-7499
DOI - 10.46795/ijhcbs.v3i1.270
Subject(s) - agra , tuberculosis , medicine , veterinary medicine , drug resistance , amikacin , ofloxacin , capreomycin , levofloxacin , traditional medicine , mycobacterium tuberculosis , multiple drug resistance , biology , microbiology and biotechnology , antibiotics , ethambutol , ciprofloxacin , pathology , ecology
Present study was aimed to determine the status of second-line anti-TB drug resistance and risk factorsfor extensively drug-resistance (XDR)-tuberculosis among multi-drug resistant (MDR)-tuberculosis patients from Agra region of Uttar Pradesh, North India.A total of 279 MDR-Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients of Agra region of Uttar Pradesh were analyzed for the resistance to second-line anti-TB drugs (SLDs). The demographic, behavioral, clinical and social information was compared with the results of drug susceptibility testing and analyzed statistically. Out of 279 MDR-isolates, 195 (69.89%) isolates were found resistant to at least one of the SLDs. The rates of general resistance to each of the drugs were as follows: kanamycin (42.29%), amikacin (17.92%), levofloxacin (40.14%) and ofloxacin (51.97%). Among the MDR-TB isolates, 53.76, 43.01 and 26.88% isolates were resistant to fluoroquinolone, second line injectable drugs and XDR, respectively. Among the demographic/ clinical variables, occupation, gender and number of family members were associated with the development of XDR-TB in MDR-TB patients of Agra region of Uttar Pradesh(P value: <0.05).Present study has provided baseline information about the risk factors associated with SLDs resistance and XDRamong MDR-TB patients which can be useful to strengthen the implementation of targeted interventions in order to minimize the cases of drug resistance tuberculosis in Uttar Pradesh, North India.